Advanced search
Publication Cover
Future Science OA Volume 5, 2019 - Issue 1
Submit an article Journal homepage
1,459
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Through AFP-Binding Receptors

Vladimir N Pak1 Freelance Researcher, TorontoM2R 3T1, CanadaCorrespondence[email protected]
Article: FSO321 | Received 20 Mar 2018, Accepted 23 May 2018, Published online: 28 Jun 2018

References

  • Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5(1), 3–8 (2017).
  • Belyaev NN, Abdolla N, Perfilueva Yu, Tleulieva R. Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSCs) and inhibits experimental tumor growth. Cancer Immunol. Immunother. 67(1), 101–111 (2017).
  • Ostrand-Rosenberg S, Sinha P, Figley C et al. Frontline science: myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. J. Leukoc. Biol. 101(5), 1091–1101 (2017).
  • Pak VN. Cancer is the innate immunity fault. Cancer Therapy & Oncol. Int. J. 6(3), 555687 (2017).
  • Fleming V, Hu X, Weber R et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 9, 1–12 (2018).
  • Dominguez G, Condamine TC, Mony S et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-1784 (2016) ( Epub ahead of print).
  • Pak V. Magic bullet and immunotherapy against metastasis. J. Cancer Prev. Curr. Res. 6(3), 00206 (2016).
  • Pak V. Achilles heel of cancer. Cancer Therapy & Oncol. Int. J. 3(5), 555625 (2017).
  • Govallo VI. The Immunology of Pregnancy and Cancer. Nova Science Publishers, NY, USA (1993).
  • Severin SE, Rodina AV, Nitsvetov MB et al. Regulation of antitumor activity using monoclonal antibodies to alpha-fetoprotein receptor and after immunization with this protein. Russ. J. Immunol. 6(3), 249–256 (2001).
  • Frantsev AP, Frantseva IA. KZ 15693 (2010). http://kzpatents.com/patents/francev-aleksandr-pavlovich.
  • Pak VN, Belyaev NN. Alpha-fetoprotein-mediated immune tolerance and its reversal. In: Alpha-fetoprotein: Functions and Clinical Applications. Lakhi N, Moretti M ( Eds). Nova Science Publishers, NY, USA, 353–374 (2016).
  • Celecure AS. US6878688 (2005).
  • Pak V. The use of alpha-fetoprotein for the delivery of cytotoxic payloads to cancer cells. Ther. Deliv. 5(8), 885–892 (2014).
  • Arshad NM, In LLA, Soh TL et al. Recombinant human alpha fetoprotein synergistically potentiates the anti-cancer effects of 1′-S-1′-acetoxychavicol acetate when used as a complex against human tumours harbouring AFP-receptors. Oncotarget 6, 16151–16167 (2015).
  • University Health Network: WO/2016/119045 (2016).
  • Zubkova E, Semenkova L, Dudich E, Dudich I, Parfyonova Y, Menshikov M. Alpha-fetoprotein contributes to THP-1 cell invasion and chemotaxis via protein kinase and Gi-protein-dependent pathways. Mol. and Cell Biochem. 379(1–2), 283–293 (2013).
  • Pak VN. The use of alpha-fetoprotein for treatment of autoimmune diseases and cancer. Ther. Deliv. 9(1), 37–46 (2017).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.